Galapagos (GB:0JXZ) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Galapagos has announced promising results from its phase 1/2 study of the CD19 CAR T-cell therapy GLPG5101 in treating relapsed/refractory non-Hodgkin lymphoma, demonstrating high anti-tumor activity and a favorable safety profile. The study highlights the effectiveness of Galapagos’ decentralized manufacturing platform, which allows for the quick delivery of fresh CAR T-cells, achieving a vein-to-vein time of just seven days. These advances offer significant potential for improving patient outcomes in rapidly progressing cancers.
For further insights into GB:0JXZ stock, check out TipRanks’ Stock Analysis page.
